Search hospitals
>
District of Columbia
>
Washington
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Claim this profile
Washington, District of Columbia 20007
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Pancreatic Cancer
Conducts research for Lymphoma
Conducts research for Leukemia
377 reported clinical trials
20 medical researchers
Summary
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Lymphoma, Leukemia and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 333 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Stephen V. Liu, Claudine Isaacs, MD, and Chul Kim.
Area of expertise
Breast Cancer
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center has run 59 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center has run 40 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Benjamin A. Weinberg
MedStar Georgetown University Hospital
2 years of reported clinical research
Stephen V. Liu
MedStar Georgetown University Hospital
9 years of reported clinical research
Claudine Isaacs, MD
Georgetown University
4 years of reported clinical research
Chul Kim
MedStar Georgetown University Hospital
3 years of reported clinical research
Clinical Trials running at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Thyroid Cancer
KRAS Mutation
Solid Tumors
Colon Cancer
Thrombocytopenic Purpura
Tumors
BRAF Mutation
Cancer Vaccine
for Lung Cancer
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Recruiting
2 awards
Phase 3
2 criteria
Chemo-Immunotherapy
for Lung Cancer
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement.. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.
Recruiting
1 award
Phase 2
3 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Recruiting
1 award
Phase 2
19 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center?
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Lymphoma, Leukemia and other specialties. Lombardi Comprehensive Cancer Center at Georgetown University Medical Center is involved with conducting 377 clinical trials across 333 conditions. There are 20 research doctors associated with this hospital, such as Benjamin A. Weinberg, Stephen V. Liu, Claudine Isaacs, MD, and Chul Kim.
Where is Lombardi Comprehensive Cancer Center at Georgetown University Medical Center located?
The Lombardi Comprehensive Cancer Center, situated at 3970 Reservoir Road NW, Washington, D.C., is affiliated with MedStar Georgetown University Hospital and focuses on advancing cancer research. It offers a comprehensive range of cancer care services, from screening and prevention to diagnosis, treatment, rehabilitation, and survivorship programs. This center is an integral part of the Georgetown University Medical Center.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Lombardi Comprehensive Cancer Center at Georgetown University Medical Center: - **MedStar Health Home Care Patient Financial Services:** Call 301-931-6125 or toll-free at 877-931-3100 ext. 6125. - **Hospital Billing Concerns:** Call 410-933-2424 or toll-free at 800-280-9006. - **Physician Billing Concerns:** Call 703-558-1400 or toll-free at 888-896-1400.
What insurance does Lombardi Comprehensive Cancer Center at Georgetown University Medical Center accept?
The Lombardi Comprehensive Cancer Center, located within MedStar Georgetown University Hospital, accepts most major health insurance plans. Coverage for specific services may vary, so patients are advised to contact their insurance provider to confirm coverage details.
What awards or recognition has Lombardi Comprehensive Cancer Center at Georgetown University Medical Center received?
Lombardi Comprehensive Cancer Center, located at Georgetown University Medical Center in Washington, D.C., is distinguished as the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center in the area. It serves as the research cornerstone for the MedStar Georgetown Cancer Institute. Additionally, it collaborates with John Theurer Cancer Center at Hackensack University Medical Center in New Jersey as part of an NCI Comprehensive Cancer Center research consortium, emphasizing studies on innovative cancer treatments and technologies to improve patient outcomes.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.